Analysis of leukemia stem cell regulation by leukemia oncogene Evi-1
Project/Area Number |
21890055
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Hematology
|
Research Institution | The University of Tokyo |
Principal Investigator |
SATO Tomohiko The University of Tokyo, 医学部附属病院, 特任臨床医 (90553694)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥1,235,000 (Direct Cost: ¥950,000、Indirect Cost: ¥285,000)
Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
|
Keywords | 癌 / 白血病 / 幹細胞 |
Research Abstract |
We have recently generated Evi-1-GFP knock-in mice, which can trace Evi1 mRNA level in vivo, and we revealed that Evi-1 is highly expressed at both fetal and adult hematopoietic stem cells (HSCs). In addition, we also clarified that Evi-1 positive murine HSC (KSL) function as long-term HSC by bone marrow transplantation assay, and that Evi-1 can mark long-term HSC which is the most immature hematopoietic cells. (These data are now on submission) Next, for the analysis of leukemia stem cell regulation by Evi-1, we made chronic myeloid leukemia (CML) mouse of Evi-1-GFP knockin origin by using BCR-ABL oncogene. We revealed that Evi-1 positive KSL cells had highest Evi-1 expression in these model mice which implied that Evi-1 could regulate CML stem cells. Our original analysis of leukemia stem cell is still ongoing for the purpose of establishing specific therapy of CML stem cells.
|
Report
(3 results)
Research Products
(5 results)
-
[Presentation] Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System2010
Author(s)
Keisuke Kataoka, Tomohiko Sato, Akihide Yoshimi, Susumu Goyama, Takako Tsuruta, Shunya Arai, Yoichi Imai, Katsuyoshi Kumagai, Naoto Kubota, Takashi Kadowaki, Mineo Kurokawa
Organizer
52nd American Society of Hematology Annual Meeting (838)
Place of Presentation
Orlando, USA.(Oral presentation)
Related Report
-
-
-
-